IHLO-DTI: Drug-Target Interaction Prediction Based on Improved Hypergraph Neural Network and Laplacian Matrix Optimization
ACS Synthetic Biology · 2026
DOI: 10.1021/acssynbio.6c00326 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2026. Verfasst von Guolongwei Dai und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Computer Science, Sichuan University, Chengdu610065, Sichuan, China. Hauptthemen laut MEDLINE: Drug Discovery, Proteins, Neural Networks, Computer. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Science and Technology Innovation 2030, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Accurate prediction of drug-target interactions is pivotal for accelerating drug discovery and drug repurposing. However, existing advanced methods often fail to effectively characterize the many-to-many interactions between drugs and targets. Furthermore, they struggle to fully mine the structural features of drugs and proteins. To address these limitations, we propose IHLO-DTI, a novel prediction model based on an improved hypergraph neural network and Laplacian matrix optimization. First, we construct drug, protein, and drug−protein pair hypergraphs, where shared-drug and shared-target relationships are used to characterize multi-target activity and shared-target regulation. We then optimize hyperedge weights using a Laplacian matrix to enhance biologically meaningful high-order associations and suppress potential noise. Second, we use simplified graph convolution and graph convolutional network to extract global and local features, enabling efficient modeling of multi-level semantic information for drugs and targets. Next, we introduce a cross-attention mechanism and a dynamic gating module to perform fine-grained fusion of multi-channel features, improving the representation of cross-modal information interactions. Finally, we jointly train the model with contrastive learning and cross-entropy loss to enhance the consistency and discriminability of the learned representations. IHLO-DTI achieves mean AUROC and AUPR values of 0.9777 and 0.9716, respectively, on two public datasets. IHLO-DTI can effectively capture high-order many-to-many interactions between drugs and targets, improving prediction accuracy and robustness. It provides a more reliable computational tool for clinical drug screening, repurposing, and precision medicine research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Computer Science, Sichuan University, Chengdu610065, Sichuan, China.
- Department of Rehabilitation Medicine, West China Hospital of Sichuan University, Chengdu610041, Sichuan, China.
ORCID-Profile: Tao Luo
Förderung
- National Science and Technology Innovation 2030, Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Dai, G., Luo, T., Li, D., Liu, Z., Gu, J., Fan, L., Lin, T., Wei, Q., & Wang, F. (2026). IHLO-DTI: Drug-Target Interaction Prediction Based on Improved Hypergraph Neural Network and Laplacian Matrix Optimization. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.6c00326
Vancouver
Dai G, Luo T, Li D, Liu Z, Gu J, Fan L, et al. IHLO-DTI: Drug-Target Interaction Prediction Based on Improved Hypergraph Neural Network and Laplacian Matrix Optimization. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.6c00326
BibTeX
@article{Dai2026,
author = {Dai, Guolongwei and Luo, Tao and Li, Dandan and Liu, Zeping and Gu, Jiaying and Fan, Lingjie and Lin, Tao and Wei, Quan and Wang, Fengyi},
title = {IHLO-DTI: Drug-Target Interaction Prediction Based on Improved Hypergraph Neural Network and Laplacian Matrix Optimization},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.6c00326}
}
EUVIMED